An interventional study of Eyerising RS-200-2A and Eyerising SLX-1A in Myopia, sponsored by Ruihua Wei. Enrolling by invitation at 1 site in China. Open to participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by Ruihua Wei · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 220 studies in Myopia with a site in China — 81 open to participants now, 101 under way, 4 of them phase 3. Myopia · China.
Among the 220 studies in Myopia with a site in China, this one is the 126th largest by planned enrollment of the 154 interventional ones that give a count, is one of 21 that started in 2025, is one of 135 with no phase, reaches primary completion later than 40 of the 100 other live ones, and was the 180th registered.
1,162 studies on the registry are indexed under Myopia; 228 are open to participants now.
Browse Myopia studies →81 of the 220 studies in Myopia with a site in China are open now. Recruiting first, the newest first:
Shanghai Eye Disease Prevention and Treatment Center · Sites in China
Ages 3–6
Beijing Tongren Hospital · Sites in China
Healthy volunteers
Zhongshan Ophthalmic Center, Sun Yat-sen University · Sites in China
Ages 6–18 · Healthy volunteers
CooperVision International Limited (CVIL) · Sites in China
Ages 8–10
Shanghai Eye Disease Prevention and Treatment Center · Sites in China
Ages 6–11 · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 122 Myopia studies recruiting now, 19 (16%) set no upper age limit and 102 (84%) stop at 75 or younger; 86 take children under 18; 53 take healthy volunteers.
This study: 18 Years to 35 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
220 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 8 · Phase 4 7
First in 2005; this study’s year is marked. 21 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 79 across 926 interventional studies indexed under Myopia.
Median enrollment 149 across the 154 interventional studies, 1,000 across the 66 observational. Of the 76 that completed or were terminated, 5 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 220 have an industry lead sponsor. The 10 most frequent:
Ruihua Wei is the lead sponsor of 5 studies on the registry; 4 are open to participants now.
Ruihua Wei has 5 studies filed under Myopia — fewer than ten, so there is no comparison to draw.
33 of the studies in Myopia with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06708156Phase 3Oupushifang Pharmaceutical Technology Co., Ltd.The Effectiveness and Safety of Two Low-concentration Atropine Sulfate Eye Drops (0.01%/0.02%) for Delaying the Pediatric Myopia Progression | 2026-12-31 |
| NCT05850936Sun Yat-sen UniversityEffect of IOP Lowering on Progressive HM | 2026-11-20 |
| NCT07585877Zhongda HospitalEffect of Branched-Chain Amino Acid Supplementation on Myopia Progression | 2026-12-30 |
| NCT07119723Tianjin Medical University Eye HospitalEnvironmental Factors and Myopia Prevalence Among Uyghur Students in Remote China | 2026-12-30 |
| NCT06667037Zhongshan Ophthalmic Center, Sun Yat-sen UniversityOrthokeratology and 0.01% Atropine Sequential Treatment for Myopia Control | 2026-12-31 |
Add all 33 to your calendar (.ics) → With an account.
Among the 220 studies in Myopia with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To explore the effectiveness and safety of repeated exposure to repeated low-intensity red light
The experiment will be divided into two phases. In the first phase, the subjects will be randomly grouped using laser equipment, LED equipment and control group. Each experimental group will be exposed to the red light twice a day for one month. The second stage involves self-comparison of the laser equipment, with the usage frequencies being once a day and three times a day.
To explore the effectiveness and safety of repeated exposure to repeated low-intensity red light in different devices and frequencies, as well as its impact on the axial length, spherical equivalent refraction and choroidal thickness of myopia progression.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Use Eyerising (RS-200-2A), 1 time,2 times or 3 times a day
Device: Eyerising RS-200-2A
Use Eyerising(SLX-1A), 2 times a day
Device: Eyerising SLX-1A
Eyerising RS-200-2A,1 time,2 times, 3 times a day
Eyerising SLX-1A, 2 times a day
Axial length
Time frame: From enrollment to the end of treatment up to 7 months
Spherical equivalent
Time frame: From enrollment to the end of treatment up to 7 months
Choroidal thickness
Time frame: From enrollment to the end of treatment up to 7 months
Plan to share: No
No publications or documents are linked to this record.
Ran from Sep 2025 to primary completion in Jun 2026, 9 months.
Of 200 non-industry interventional studies with no phase under Myopia, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's 9 months is below that.
Counting every sponsor, half of 434 studies reached it within 14 months; a quarter within 3 and three quarters within 34.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: primary completion Mar 2026 → Jun 2026 and completion Jun 2026 → Dec 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ruihua Wei